Sign in

CIK 0001799448

  • Non-accelerated filer
  • Smaller reporting company

Aligos Therapeutics, Inc.

Sign in to watch
Ticker
ALGS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 800-466-6059
Business address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-06-25 Nuechterlein Carole Director Grant or award · Stock Option (Right to Buy) +5,860 5,860
2025-06-25 Nuechterlein Carole Director Grant or award · Stock Option (Right to Buy) +5,860 5,860
2024-06-27 Nuechterlein Carole Director Grant or award · Stock Option (Right to Buy) +60,000 60,000
2024-02-28 Nuechterlein Carole Director Grant or award · Stock Option (Right to Buy) +4,411 4,411
2024-02-27 Nuechterlein Carole Director Returned to the company · Stock Option (Right to Buy) −15,000 0
2023-10-25 Nuechterlein Carole Director Purchase +7,933,601 $0.76 $6.0M 11,025,941
2023-10-25 Nuechterlein Carole Director Purchase · Warrant (Right to Buy) +3,966,800 $0.13 $496K 3,966,800
2023-07-20 Nuechterlein Carole Director Grant or award · Stock Option (Right to Buy) +20,000 20,000
2022-06-23 Nuechterlein Carole Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2021-06-17 Nuechterlein Carole Director Grant or award · Stock Option (Right to Buy) +15,000 15,000
2020-10-20 Nuechterlein Carole Director Conversion +2,145,991 2,145,991
2020-10-20 Nuechterlein Carole Director Conversion +662,799 2,808,790
2020-10-20 Nuechterlein Carole Director Conversion +283,550 3,092,340
2020-10-20 Nuechterlein Carole Director Conversion · Series A Preferred Stock −2,145,991 0
2020-10-20 Nuechterlein Carole Director Conversion · Series B-1 Preferred Stock −662,799 0
2020-10-20 Nuechterlein Carole Director Conversion · Series B-2 Preferred Stock −283,550 0

Page 1 of 1 · 16 trades